ProCE Banner Activity

CME

Precision Medicine in Severe Asthma: How Phenotypes and Endotypes Guide Treatment Decisions

Multimedia
This activity will break down the differences between Type 2 and non-Type 2 asthma and discuss how making that differentiation in severe asthma patients has a profound impact on treatment pathways.

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: September 13, 2019

Expiration: September 13, 2020

No longer available for credit.

Share

Faculty

Emily DiMango

Emily DiMango, MD

Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Columbia University Medical Center
New York, New York

Michael E. Wechsler

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director,
NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Provided by

Provided by the University of Cincinnati, in collaboration with ASCP and GAPNA.
ProCE Banner

Supporters

Supported by educational grants from

Novartis Pharmaceuticals Corporation

Sanofi Genzyme and Regeneron Pharmaceuticals

Target Audience

Pulmonologists, allergists, primary care physicians (PCPs), NPs, PAs and other healthcare providers who manage patients with severe asthma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the benefits and limitations of traditional asthma therapy (eg, ICS, LABAs, LAMAs, and LTRAs) for severe asthma phenotypes/endotypes.
  • Compare new and emerging phenotype/endotype-targeted agents for severe asthma.
  • Develop individualized treatment plans for patients with severe uncontrolled asthma.

Faculty Disclosure

Primary Author

Emily DiMango, MD

Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Columbia University Medical Center
New York, New York

Dr. DiMango discloses the following: Advisory Board: AstraZeneca

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director,
NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Dr. Wechsler discloses the following: Grants/Research Support: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron Consultant: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron, Genetech/Novartis

Instructions for Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation:

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Program Medium

This program has been made available online.